Ocular Therapeutix (NASDAQ:OCUL) Now Covered by William Blair

William Blair began coverage on shares of Ocular Therapeutix (NASDAQ:OCUL - Free Report) in a report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating on the biopharmaceutical company's stock. William Blair also issued estimates for Ocular Therapeutix's Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.23) EPS and FY2026 earnings at ($1.16) EPS.

A number of other equities analysts also recently commented on OCUL. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. Needham & Company LLC reaffirmed a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $16.38.

Ocular Therapeutix Trading Up 10.9 %

Ocular Therapeutix stock traded up $0.70 during trading on Tuesday, hitting $7.11. The company's stock had a trading volume of 1,589,232 shares, compared to its average volume of 1,567,917. The stock's fifty day moving average is $7.24 and its 200 day moving average is $8.58. Ocular Therapeutix has a 1-year low of $4.06 and a 1-year high of $11.78. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -5.39 and a beta of 1.49. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. As a group, equities research analysts predict that Ocular Therapeutix will post -0.98 EPS for the current year.

Insiders Place Their Bets

In other news, insider Donald Notman sold 6,301 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $7.84, for a total value of $49,399.84. Following the transaction, the insider now directly owns 204,563 shares in the company, valued at approximately $1,603,773.92. This trade represents a 2.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,895 shares of company stock valued at $283,772 in the last quarter. Insiders own 3.50% of the company's stock.

Institutional Trading of Ocular Therapeutix

A number of institutional investors and hedge funds have recently made changes to their positions in OCUL. GF Fund Management CO. LTD. acquired a new position in Ocular Therapeutix during the 4th quarter valued at approximately $28,000. Atlas Capital Advisors Inc. acquired a new position in shares of Ocular Therapeutix during the fourth quarter valued at $43,000. AlphaQuest LLC bought a new position in shares of Ocular Therapeutix during the fourth quarter worth about $53,000. GAMMA Investing LLC increased its holdings in shares of Ocular Therapeutix by 6,760.0% in the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 8,112 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Ocular Therapeutix by 2,045.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 8,446 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.